Alimentary pharmacology & therapeutics · 2025
A Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Murthy Sanjay K, Ahmed Faria, Pugliese Michael, Taljaard Monica, Tandon Parul, Matthews Priscilla, Kaplan Gilaad G, Coward Stephanie, Bernstein Charles N, Benchimol Eric I, Kuenzig M Ellen, Targownik Laura E, Singh Harminder, Canadian Gastro‐Intestinal Epidemiology Consortium (CanGIEC)
Аннотация
BACKGROUND: Trends in extra-digestive (ED) cancer incidence and mortality in inflammatory bowel diseases (IBD) may be changing with newer approaches to management.
AIMS: To study temporal trends and contemporary risks of ED cancers in individuals with and without IBD.
METHODS: Using population-level administrative data from Ontario, Canada, we studied ED cancer rates among individuals with IBD and age-sex-matched controls (1:10) without IBD between 1994 and 2020. We modelled age-sex-standardised annual cancer incidence (per 100,000 person-years) over time by first-order linear autoregression, and standardised cancer incidence and mortality rate ratios (SIR, SMR) by quasi-Poisson regression.
RESULTS: The average annual percentage change (AAPC) in ED cancer incidence was stable among 110,919 people with IBD (0.108%/year; 95% CI, -0.380, 0.599) but declined among 1,109,190 matched controls (-1.39%/year; 95% CI, -1.57, -1.21). Among those with IBD, AAPC was significant for non-Hodgkin's lymphoma (1.48%/year; 95% CI, 0.161, 2.82), melanoma (1.77%/year; 95% CI, 0.781, 2.77), cervical (2.31%/year; 95% CI, 0.602, 4.10), uterine (4.41%/year; 95% CI, 0.045, 8.96) and thyroid (8.10%/year; 95% CI, 4.31, 12.0) cancers, and statistically greater than controls for cervical, ovarian, lung, and bladder cancers. During 2010-2020, ED cancer incidence was higher in those with IBD (SIR 1.20; 95% CI 1.15, 1.26), while ED cancer-related mortality was specifically higher in those with Crohn's disease (CD; SMR 1.31; 95% CI 1.14, 1.51), as compared to matched controls.
CONCLUSIONS: ED cancer incidence has not changed among those with IBD but has declined among matched controls. Beyond 2010, ED cancer incidence is higher among those with IBD and cancer-related mortality is higher among those with CD, relative to matched controls.
AIMS: To study temporal trends and contemporary risks of ED cancers in individuals with and without IBD.
METHODS: Using population-level administrative data from Ontario, Canada, we studied ED cancer rates among individuals with IBD and age-sex-matched controls (1:10) without IBD between 1994 and 2020. We modelled age-sex-standardised annual cancer incidence (per 100,000 person-years) over time by first-order linear autoregression, and standardised cancer incidence and mortality rate ratios (SIR, SMR) by quasi-Poisson regression.
RESULTS: The average annual percentage change (AAPC) in ED cancer incidence was stable among 110,919 people with IBD (0.108%/year; 95% CI, -0.380, 0.599) but declined among 1,109,190 matched controls (-1.39%/year; 95% CI, -1.57, -1.21). Among those with IBD, AAPC was significant for non-Hodgkin's lymphoma (1.48%/year; 95% CI, 0.161, 2.82), melanoma (1.77%/year; 95% CI, 0.781, 2.77), cervical (2.31%/year; 95% CI, 0.602, 4.10), uterine (4.41%/year; 95% CI, 0.045, 8.96) and thyroid (8.10%/year; 95% CI, 4.31, 12.0) cancers, and statistically greater than controls for cervical, ovarian, lung, and bladder cancers. During 2010-2020, ED cancer incidence was higher in those with IBD (SIR 1.20; 95% CI 1.15, 1.26), while ED cancer-related mortality was specifically higher in those with Crohn's disease (CD; SMR 1.31; 95% CI 1.14, 1.51), as compared to matched controls.
CONCLUSIONS: ED cancer incidence has not changed among those with IBD but has declined among matched controls. Beyond 2010, ED cancer incidence is higher among those with IBD and cancer-related mortality is higher among those with CD, relative to matched controls.